Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional) | PAR 20 035

Opportunity Information: Apply for PAR 20 035

The NIH grant opportunity "Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)" (Funding Opportunity Number PAR-20-035) supports research focused on polysubstance use, meaning the use of more than one drug (including alcohol and other substances) in ways that may overlap in time, context, or pattern. The announcement is backed by the Collaborative Research on Addiction (CRAN), a trans-NIH partnership that brings together the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). In practical terms, this signals an interest in research that can connect addiction science across substances and across health outcomes, including broader public health impacts that can intersect with cancer-related risks and comorbidities.

The FOA has two main scientific goals. First, it aims to clarify how polysubstance use changes the brain, behavior, and health outcomes in ways that may be different from, or similar to, what is seen with single-substance use. This includes neurobiological alterations (for example, changes in reward, stress, learning, executive function, or other neural systems), behavioral effects (such as risk-taking, impaired decision-making, escalation of use, withdrawal-related behaviors, or relapse vulnerability), and public health consequences (including overdose risk, infectious disease transmission, mental health comorbidity, injury, and other downstream harms). A key theme is comparative understanding: investigators are encouraged to directly examine whether combined or sequential use produces additive, synergistic, or distinct effects relative to using only one drug.

Second, the opportunity is designed to push polysubstance research to be integrative across a translational pipeline rather than isolated within one research silo. The FOA explicitly highlights three broad translational stages that can be linked together: basic science research in animals, human-based laboratory investigations, and epidemiological studies. That means an application might start with mechanistic work in animal models, move into controlled human laboratory paradigms to test behavioral or physiological responses, and/or extend into population-level data to examine real-world patterns, risk factors, and outcomes. The expectation is not simply to run parallel studies, but to connect insights across levels of analysis so findings inform each other.

To make that cross-stage integration happen quickly, the FOA uses the Exploratory/Developmental Phased Award mechanism (R61/R33). This two-phase structure is meant to support faster iteration than a traditional single-project grant. During the R61 phase, teams can conduct polysubstance research at any one of the translational stages (animal, human lab, or epidemiology). The R33 phase then supports rapid "back- or forward-integration" into another stage, meaning results from the first phase are expected to drive the next step in a different translational domain. For example, an R61 epidemiology analysis might identify a high-risk combination or sequence of use that then becomes the basis for an R33 human laboratory study examining mechanisms or acute effects. Conversely, an R61 animal study identifying a neural pathway implicated in combined drug exposure could be translated in R33 into human laboratory measures or epidemiological markers that test whether the mechanism aligns with real-world outcomes. The central idea is bidirectional exchange: basic discoveries inform human and population research, while real-world patterns and risks inform mechanistic experiments.

The FOA is designated "Clinical Trial Optional," which means applicants may propose studies that meet the NIH definition of a clinical trial, but they are not required to do so. This provides flexibility for projects that are purely mechanistic or observational as well as those that involve interventions or prospectively assigned conditions, depending on the scientific question and the chosen translational stage.

Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations and tribal governments that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other entities. The announcement also explicitly calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-U.S. entities (foreign organizations), and U.S. territories or possessions. This wide eligibility reflects the cross-cutting nature of polysubstance problems and the value of including community, clinical, and international perspectives where appropriate.

From an administrative standpoint, the opportunity is an NIH discretionary grant in the education and health activity category, with CFDA numbers 93.273, 93.279, and 93.399 listed in the source data. The FOA was created on 2019-10-18, and the original closing date shown is 2022-11-07. The source excerpt does not provide an award ceiling or expected number of awards, so those details would typically be confirmed by checking the full FOA text and any associated NIH notices.

Overall, this FOA is best viewed as a push for integrated, faster-moving polysubstance science that can explain what is unique about using multiple substances, identify mechanisms and risk pathways, and connect laboratory and population evidence in a way that accelerates translation. It is aimed at projects that do more than document co-use; it favors research that disentangles mechanisms, compares polysubstance versus single-substance effects, and uses the two-phase R61/R33 design to move findings across research stages in a deliberate, structured way.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279, 93.399.
• This funding opportunity was created on 2019-10-18.
• Applicants must submit their applications by 2022-11-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 20 035

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: